Hong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hong Chen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Ke Jin
Department of Urology, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publicationShen Lin
Department of Urology, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publicationShengqiang Huang
Department of Urology The People's Hospital of Pujiang County Jinhua Zhejiang China
1 shared publication- Shuixiang Tao
Department of Urology Shaoxing People's Hospital (Zhejiang University Shaoxing Hospital) Shaoxing Zhejiang China
1 shared publication Yiwei Lin
Department of Urology, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publication
Latest Publications
- Open Access
- 30 October 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (22) , 21013-21021
Circulating inflammatory cytokines in relation to the risk of renal cell carcinoma: A gender‐specific two‐sample Mendelian randomization study
Background: Currently there is no specific molecular biomarker for the diagnosis and treatment of renal cell carcinoma (RCC). Here we performed a gender‐specific two‐sample Mendelian randomization analysis to systematically assess the effects of circulating cytokines on RCC.Methods: We have employed cis‐quantitative trait loci as instrumental variables for the protein levels and expression of circulating cytokines. We estimated the causal effects of circulating cytokines on RCC risk in males and females with several Mendelian randomization methods.Results: We observed a significant causal effect of Eotaxin on the increased risk of RCC in males (Odds ratio [OR] = 2.546, 95% confidence interval [CI] = 1.617–4.010, p value = 5.496 × 10–5), but not in females (OR = 1.352, 95% CI = 0.766–2.388, p value = 0.298). Besides, we also identified several cytokines as potentially associated with RCC in males including RANTES, MCP3, PDGFbb, TRAIL, and several other cytokines as potentially associated with RCC in females including sICAM and SCGFb.Conclusion: Our study highlighted that a higher level of circulating Eotaxin is causally associated with an increased risk of RCC in males but not in females. Further studies are needed to elucidate the exact mechanism and its potential application in the prognosis and treatment of RCC.
- 30 October 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (22) , 21013-21021
Open AccessCirculating inflammatory cytokines in relation to the risk of renal cell carcinoma: A gender‐specific two‐sample Mendelian randomization study
Background: Currently there is no specific molecular biomarker for the diagnosis and treatment of renal cell carcinoma (RCC). Here we performed a gender‐specific two‐sample Mendelian randomization analysis to systematically assess the effects of circulating cytokines on RCC.Methods: We have employed cis‐quantitative trait loci as instrumental variables for the protein levels and expression of circulating cytokines. We estimated the causal effects of circulating cytokines on RCC risk in males and females with several Mendelian randomization methods.Results: We observed a significant causal effect of Eotaxin on the increased risk of RCC in males (Odds ratio [OR] = 2.546, 95% confidence interval [CI] = 1.617–4.010, p value = 5.496 × 10–5), but not in females (OR = 1.352, 95% CI = 0.766–2.388, p value = 0.298). Besides, we also identified several cytokines as potentially associated with RCC in males including RANTES, MCP3, PDGFbb, TRAIL, and several other cytokines as potentially associated with RCC in females including sICAM and SCGFb.Conclusion: Our study highlighted that a higher level of circulating Eotaxin is causally associated with an increased risk of RCC in males but not in females. Further studies are needed to elucidate the exact mechanism and its potential application in the prognosis and treatment of RCC.